Patent Intelligence · Domain Comparison
PharmaceuticalsvsGene Editing
Side-by-side comparison across 8 patent dimensions: portfolio size, citation quality, concentration, prosecution speed, claim breadth, expiry opportunity, and filing velocity.
Pharmaceuticals
Patents
124
Citations
47,055
Avg citations
379.5
3yr CAGR
+14.5%
HHI
238
Expiring ≤2029
2.3%
Avg prosecution
43 mo
Avg claims
23.7
Gene Editing
Patents
21
Citations
19,867
Avg citations
946.0
3yr CAGR
0.0%
HHI
930
Expiring ≤2029
0.0%
Avg prosecution
40 mo
Avg claims
31.2
Head-to-Head Comparison
| Metric | Pharmaceuticals | Gene Editing |
|---|---|---|
| Total patents | 124▲ | 21 |
| Total citations | 47,055▲ | 19,867 |
| Avg citations/patent | 379.5 | 946▲ |
| 3-year CAGR | +14.5%▲ | 0.0% |
| HHI concentration | 238▲ | 930 |
| Expiring ≤2029 | 2.3%▲ | 0.0% |
| Avg prosecution (mo) | 43 | 40▲ |
| Avg claims/patent | 23.7 | 31.2▲ |
▲ = higher is better for that metric. HHI: lower = more competitive landscape.
Grant Trend 2015–Present
Patents granted per year by domain.
2016
2018
2020
2022
2024
Domain A
Domain B
Other comparisons